$35.34
-0.29 (-0.81%)
Open$35.45
Previous Close$35.63
Day High$35.51
Day Low$34.47
52W High$43.66
52W Low$15.93
Volume—
Avg Volume150.8K
Market Cap714.08M
P/E Ratio—
EPS$-3.16
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
-28.9% upside
Current
$35.34
$35.34
Target
$25.14
$25.14
$17.03
$25.14 avg
$37.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 808.7K | 64.19M | 65.56M |
| Net Income | -65,643,442 | 8.40M | 8.13M |
| Profit Margin | -8,123.7% | 13.1% | 12.4% |
| EBITDA | -70,237,992 | 15.55M | 13.35M |
| Free Cash Flow | — | 10.13M | 9.92M |
| Rev Growth | — | +4.7% | +24.1% |
| Debt/Equity | 0.00 | 0.89 | 0.79 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |